Raul Mendoza Ayala, MD
Pulmonary Disease · Green Bay, WINPI 1619903218
Payments from drug & device makers
What this record shows
The money is spread across several categories — travel and lodging (45.8%), education and food and beverage — rather than concentrated in one kind of arrangement. 7 manufacturers reported payments, led by Intuitive Surgical at 56.4% of the total. Reporting peaked in 2024 at $4,699 and has fallen 97.9% since, to $100 in 2025.
Across 42 payments — averaging $170.07 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Intuitive Surgical$4K
- Pulmonx Corporation$3K
- Johnson & Johnson$341
- Sunovion Pharmaceuticals Inc.$37
- Olympus Corporation Of The Americas$26
- CSL Behring$22
- plus $15 from 1 others
Across 7 payments — averaging $9406.60 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- AstraZeneca$42K
- Sanofi US Services Inc.$24K
What the payments were for
- Travel & lodging$3,27046%
- Food & beverage$1,22117%
- Education$2,65237%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Intuitive Surgical | 15 | $4,028 |
| Pulmonx Corporation | 12 | $2,674 |
| Johnson & Johnson | 6 | $341 |
| Sunovion Pharmaceuticals Inc. | 5 | $37 |
| Olympus Corporation Of The Americas | 1 | $26 |
| CSL Behring | 1 | $22 |
| United Therapeutics Corporation | 2 | $15 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$7,143 in reported general payments places this provider in the 80th percentile of 247 pulmonary disease providers in Wisconsin.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Bosentan | 12 | $15,098 |
| Fluticasone-SalmeterolFluticasone Propion/Salmeterol | 19 | $2,011 |
| Varenicline Tartrate | 13 | $1,330 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 36 | $656 |
| Ipratropium Bromide | 11 | $333 |
| Prednisone | 40 | $187 |
| Sulfamethoxazole-TrimethoprimSulfamethoxazole/Trimethoprim | 15 | $41 |
Paid to pharmacies, not to this prescriber.
Other pulmonary disease in Green Bay
- Manar Al ShahrouriGreen Bay$61K
- Prince NtiamoahGreen Bay$37K
- Musab NusratGreen Bay$12K
- Jeremy RenzGreen Bay$10K
- Fazal RaziqGreen Bay$8K
- Ramya GorthiGreen Bay$6K
- Pamela SudGreen Bay$4K
- Jonathan KurmanMilwaukee$803K
- Mouhammed RihawiMilwaukee$713K
- Hasnain BawaadamKenosha$686K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.